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The window of opportunity is a concept critical to rheumatoid arthritis treatment. Early treatment changes the
outcome of rheumatoid arthritis treatment, in that response rates are higher with earlier disease-modifying
anti-rheumatic drug treatment and damage is substantially reduced. Axial spondyloarthritis is an inflammatory axial
disease encompassing both nonradiographic axial spondyloarthritis and established ankylosing spondylitis. In axial
spondyloarthritis, studies of magnetic resonance imaging as well as tumor necrosis factor inhibitor treatment
and withdrawal studies all suggest that early effective suppression of inflammation has the potential to reduce
radiographic damage. This potential would suggest that the concept of a window of opportunity is relevant not
only to rheumatoid arthritis but also to axial spondyloarthritis. The challenge now remains to identify high-risk
patients early and to commence treatment without delay. Developments in risk stratification include new
classification criteria, identification of clinical risk factors, biomarkers, genetic associations, potential antibody
associations and an ankylosing spondylitis-specific microbiome signature. Further research needs to focus on
the evidence for early intervention and the early identification of high-risk individuals.Axial spondyloarthritis (axSpA) is an inflammatory dis-
ease of the axial skeleton and pelvis. Regardless of
whether it progresses onto ankylosing spondylitis (AS),
axSpA has an appreciable disease burden. axSpA is also
associated with co-morbidities such as uveitis, psoriasis,
inflammatory bowel disease, cardiovascular disease,
osteoporosis and significant loss of work productivity.
There is emerging evidence that early treatment may
change the outcome in axSpA.
The window of opportunity is a concept of critical im-
portance in rheumatoid arthritis (RA). Early treatment
results in reductions of disease activity, joint erosions,
and better treatment responses the earlier disease-
modifying anti-rheumatic drugs are commenced. It also
results in a greater proportion of patients in drug-free
remission after treatment withdrawal. These findings
have led to changes in RA treatment paradigms, with in-
creasing emphasis on early diagnosis and treatment.
So how is this concept relevant to axSpA? A number
of studies have demonstrated early treatment that* Correspondence: philip.robinson@uq.edu.au
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axSpA.
Whilst initial studies suggested that radiographic pro-
gression of AS is not slowed by treatment with tumor
necrosis factor inhibitor (TNFi) medications, two obser-
vational studies have now shown a reduction in radio-
graphic progression with these agents [1,2]. One of these
studies also showed that delay in starting TNFi medica-
tions was associated with greater radiographic progres-
sion [2]. Magnetic resonance imaging (MRI) studies
have also supported the link between inflammation and
progression of ankylosis. Acute inflammatory lesions are
more likely to progress to chronic fatty lesions than
areas devoid of inflammation [3]. Vertebral corners with
inflammation on MRI are more likely to progress to syn-
desmophytes than those without [4]. There is good evi-
dence that all of the TNFi medications reduce MRI-
detected inflammatory lesions.
Intriguingly there is also new evidence that the age of
the inflammatory lesion may influence progression to
ankylosis, suggesting that a longer duration of inflamma-
tion is associated with more syndesmophyte formation.
Maksymowych and colleagues have shown that early,
acute type A lesions, without fatty metaplasia, infiltra-
tion or erosion, are less likely to progress toCentral Ltd. The licensee has exclusive rights to distribute this article, in any
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acterized by loss of signal at the vertebral corner [5].
This loss of vertebral corner signal is postulated to be
erosion, sclerosis, reparation or fatty infiltration, and
may be a sign of a more longstanding mature inflamma-
tory lesion. This work supports the theory that early cor-
ner lesions in the spine which have not developed
reparative changes of fat infiltration can potentially re-
gress, whilst more advanced corner lesions with signs of
fatty reparative change are more likely to progress to an-
kylosis. This work potentially marks fat metaplasia as an
event that precedes ankylosis and indicates that suppres-
sion of fatty change by treatment may slow progression
to ankylosis.
Taken together, these observations provide strong cir-
cumstantial evidence that treatment, especially early ef-
fective treatment, may influence radiographic outcome.
Trials of TNFi therapy in early axSpA have yielded en-
couraging results, with greater treatment responses than
in disease of longer duration. In Barkham and col-
leagues’ study of very early axSpA (mean symptom dur-
ation 15.3 months), infliximab achieved an Assessment
of SpondyloArthritis international Society (ASAS) partial
remission rate of 56% [6], compared with 22% in the
registration trial of infliximab in established AS (the
ASSERT study). Similarly, in the INFAST study of inflixi-
mab treatment in axSpA patients with disease duration
less than 3 years (mean 1.8 to 1.9 years), higher numer-
ical response rates (40% improvement from baseline
using the ASAS criteria (ASAS40) of 75%) were ob-
served than in the ASSERT study (ASAS40 of 45%) or
trials of the other TNFi agents in established AS
(ASAS40 responses of 39 to 47%) [7-10]. In the ESTHER
trial of etanercept, where symptom duration was a mean
2.9 years, ASAS40 was achieved in 70% of patients, com-
pared with ASAS40 of 45% for the etanercept trial in
established AS [8,11]. Although one should note that
these efficacy comparisons are not head to head in the
same trials, they are consistent with a difference in re-
sponse based on disease duration.
Withdrawal studies of TNFi agents in early axSpA and
AS also suggest that the frequency of drug-free remis-
sion is higher the earlier a patient is treated. In estab-
lished AS patients treated with a TNFi agent and
monitored for 6 months or more after discontinuation,
91 to 100% of patients flare [12-14]. In the INFAST trial,
40 to 48% of patients who received early infliximab
treatment remained in drug-free remission 6 months
after stopping their infliximab [15]. In the Barkham and
colleagues study mentioned above of infliximab in early
axSpA, after only four infusions 33% (four of 12) of pa-
tients remained symptom free 5 years after treatment,
whereas 100% (13 of 13) of patients initially randomized
to placebo were still requiring TNFi therapy [6,16].The definition of flare varies between studies, and
standardization of this definition as well as other issues
relating to trial design would enable better conclusions
to be drawn. However, the data do suggest that early
treatment may change the prognosis of disease. The dif-
ference between the studies may relate to study design
or exactly how large the window of opportunity is.
The major challenge now remains to accurately iden-
tify patients who have poor prognosis. The ASAS axSpA
criteria have gone some way to enabling earlier identifi-
cation of early axSpA but do have some limitations in-
cluding the ability to capture self-limiting disease
[17,18]. Clinical predictors of radiographic progression
identified to date include elevated C-reactive protein, to-
bacco smoking, and the presence of baseline syndesmo-
phytes. Other potentially promising research findings
that may enable better identification of patients who will
have persisting or bad prognosis disease include bio-
markers such as vascular endothelial growth factor,
matrix metalloprotein-3, sclerostin, citrullinated vimen-
tin and dikkopf-1. Antibodies to major histocompatibil-
ity complex class II-associated invariant-chain peptide
have been associated with axSpA by two independent
groups; if their specificity is validated in larger studies
and they become commercially available, these anti-
bodies hold great promise.
Emerging work examining the gut microbiome of
axSpA patients may provide information not only about
etiology, but also about prognosis. A distinct microbial
signature has been associated with AS (M Brown, un-
published observation). In very recent work Van Praet
and colleagues have also found an association be-
tween the degree of bowel inflammation, and MRI-
demonstrated bone marrow edema of the sacroiliac
joints [19].
Finally, clinical prediction from genetic analysis -
whilst essentially dominated by HLA-B27 until recently
- has progressed significantly, and there are now many
independent AS genetic associations [20]. This analysis
may become powerful enough in the future to enable
prediction of prognosis and particularly radiographic
severity.
There may therefore be a time when genetic analysis,
probably combined with other biomarkers or clinical
features, enables accurate prognostication of disease on-
set, features and severity. Early, or even potentially
prophylactic, treatment could then be applied to stop or
attenuate disease.
We should also acknowledge that the data currently
available are not conclusive and that a number of studies
are required before the evidence becomes compelling.
Randomized controlled trials of TNFi therapy with-
drawal in very early disease are needed, and some
are underway. Longitudinal studies of cohorts of
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stand the natural history of early disease, including re-
mission and progression rates. Further work is required
for the development of better biomarkers of early dis-
ease and case-identification strategies, which will be re-
quired to implement an early intervention strategy.
In conclusion, there is mounting evidence that early
effective treatment of inflammation in axSpA can change
disease outcome. Identification of high-risk individuals
and prompt institution of therapy is going to have in-
creasing importance in clinical practice. We should
therefore encourage industry and independent investiga-
tors to design and conduct studies in axSpA to confirm
the importance of the window of opportunity as well as
the accurate identification of high-risk individuals. Early
treatment combined with another concept borrowed
from RA, treat to target, will hopefully enable patients
to enjoy the huge therapeutic progress seen in RA to be
translated into axSpA.
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